Frédéric Tangy

This inventor holds 36 USPTO granted patents and 9 published patent applications, plus 10 CIPO patents and 18 EPO patents, primarily in Vaccine Development. Top assignees: Institut Pasteur, Centre National De La Recherche Scientifique, National Institute of Health and Medical Research. Active years: 2009-2026.

USPTO Granted Patents = 36 (Patent Applications = 9)

% Patents Active = 77.8

CIPO Patents = 10 (Patent Applications = 1)

EPO Patents = 18 (Patent Applications = 31)

Average Co-Inventor Count = 4.0

ph-index = 7

Forward Citations = 105(Granted Patents)

Company Filing History:

Centre National De La Recherche Scientifique

patents

4 out of 1,853

National Institute of Health and Medical Research

patents

4. 3 out of 156

The University of Nantes

patents

5. 2 out of 5

Institut Pasteur Du Cambodge

Ministère Des Armées - Direction Centrale Du Service De Santé Des Armées

patent

10. 1 out of 1

Ministère Des Armées—direction Centrale Du Service De Sante Des Armée

patent

11. 1 out of 3

Themis Bioscience Gmbh

patents

12. 1 out of 111

Université Paris Diderot-Paris 7

patents

where one patent can have more than one assignee

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

Vaccine Compositions

Measles Virus

RNA Viruses

Immunogenic Agents

Chimeric Polypeptides

Cancer Therapy

Negative-Strand RNA

Antiviral Agents

Recombinant Viruses

Dengue Virus

Zika Virus

SARS Coronavirus

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12533404 - COMPOSITIONS AND METHODS COMPRISING MEASLES VIRUS DEFECTIVE INTERFERING PARTICLES FOR THE PREVENTION OF INFECTIOUS DISEASES (2026-01-27),

2. 12163150 - Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions (2024-12-10),

3. 11976305 - Lassa vaccine (2024-05-07),

4. 11857616 - Recombinant measles virus expressing zika virus prM and E proteins (2024-01-02),

5. 11351246 - Recombinant measles vaccine expressing hTERT (2022-06-07),

6. 11160858 - Live recombinant measles-M2 virus—its use in eliciting immunity against influenza viruses (2021-11-02),

7. 11034730 - Dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection (2021-06-15),

8. 11020473 - Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases (2021-06-01),

9. 10980873 - Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-deltaC virus) in cancer therapy (2021-04-20),

10. 10793877 - Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions (2020-10-06),

11. 10519466 - Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions (2019-12-31),

12. 10316066 - Dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection (2019-06-11),

13. 10314905 - Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-deltaC virus) in cancer therapy (2019-06-11),

14. 10300128 - Subunit vaccine platform based on multimeric ribonucleoproteins comprising nucleoproteins of a non-segmented negative-strand RNA virus as carriers of heterologous polypeptides (2019-05-28),

15. 10227385 - Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection (2019-03-12),

Title: The Innovative Journey of Frédéric Tangy

Introduction:

Frédéric Tangy, a renowned inventor hailing from Les Lilas, France, has made significant contributions to the field of science and technology through his groundbreaking innovations.

Latest Patents:

Frédéric Tangy's latest patents focus on novel vaccine technologies aimed at combating infectious diseases and improving global health outcomes. His innovative approaches have garnered attention worldwide for their potential to revolutionize the field of immunology.

Career Highlights:

With a distinguished career spanning over two decades, Frédéric Tangy has held key positions in leading research institutions and biotechnology companies. His expertise in virology and molecular biology has led to the development of cutting-edge solutions in the fight against viral infections.

Collaborations:

Frédéric Tangy has collaborated with top scientists, researchers, and pharmaceutical companies to advance the frontiers of vaccine development. His collaborative efforts have resulted in the successful translation of scientific discoveries into tangible products that benefit society at large.

Conclusion:

In conclusion, Frédéric Tangy's relentless pursuit of innovation and his commitment to improving global health make him a trailblazer in the field of biotechnology. His pioneering work continues to inspire future generations of inventors and researchers to push the boundaries of scientific discovery.